Loading organizations...
Loading organizations...
Lentiviral vector production platform for gene therapy programs.
iVexSol has raised $38.8M across 3 funding rounds.
iVexSol has raised $38.8M in total across 3 funding rounds.
iVexSol has raised $38.8M in total across 3 funding rounds.
iVexSol's investors include Asahi Kasei Medical, BioLife Solutions, Bristol Myers Squibb, Casdin Capital, Charles River Laboratories.
iVexSol has raised $38.8M across 3 funding rounds. Most recently, it raised $23.8M Series A in January 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 26, 2023 | $23.8M Series A | Asahi Kasei Medical, BioLife Solutions, Bristol Myers Squibb, Casdin Capital, Charles River Laboratories | |
| Dec 1, 2020 | $13.0M Series A | BioLife Solutions, Casdin Capital | |
| Oct 1, 2019 | $2.0M Other Equity | BioLife Solutions, Casdin Capital |